Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

3.580 -0.060 (-1.65%)
Streaming Delayed Price Updated: 2:25 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 Next >
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
From X-Chem
Via Business Wire
Evotec Announces Change in Management Board
Via ACCESSWIRE
Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths
Via ACCESSWIRE
Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Evotec SE Provides Guidance Update
Via ACCESSWIRE
Evotec Provides Guidance Update
Via ACCESSWIRE
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Via ACCESSWIRE
Evotec SE Reports First Half-year 2024 Results on 14 August 2024
Via ACCESSWIRE
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
Via ACCESSWIRE
Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
Via ACCESSWIRE
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Via ACCESSWIRE
Evotec SE: Results of the Annual General Meeting 2024
Via ACCESSWIRE
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
Via ACCESSWIRE
Evotec Reports Q1 2024 Results and Provides Corporate Update
Via ACCESSWIRE
Evotec SE: Invitation to Conference Call
Via ACCESSWIRE
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease
Via ACCESSWIRE
Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024
Via ACCESSWIRE
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
From Centogene NV
Via GlobeNewswire
Bayer and Evotec Collaborate to Advance Precision Cardiology
Via ACCESSWIRE
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
Via ACCESSWIRE
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
Via ACCESSWIRE
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
Via ACCESSWIRE
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
Via ACCESSWIRE
Evotec welcomes Aurélie Dalbiez as Chief People Officer
Via ACCESSWIRE
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
Via ACCESSWIRE
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV
Via ACCESSWIRE
Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
Via ACCESSWIRE
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Evotec and Owkin Enter an A.I.-Powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.